Group One Trading’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Group One Trading’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,200	Closed	-$1.52M	–	8430
2023 Q1	$1.52M	Sell	14,200 -239,200	-94%	-$27.5M	0.01%	1767
2022 Q4	$27.9M	Buy	253,400 +212,400	+518%	+$13.8M	0.06%	299
2022 Q3	$2.42M	Buy	+41,000	New	+$1.88M	﹤0.01%	1749
2022 Q1	–	Sell	-35,000	Closed	-$1.38M	–	8998
2021 Q4	$1.38M	Buy	+35,000	New	+$1.1M	﹤0.01%	3000

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Group One Trading's RXDX Position: Q2 2023 in Review

Group One Trading sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 2,421 shares — an estimated $260K sold.

Group One Trading first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $260K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Group One Trading reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Group One Trading sold 2,421 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $260K.
Group One Trading first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Group One Trading's Prometheus Biosciences, Inc. Common Stock position peaked at $260K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Group One Trading's 13F filing for Q2 2023, filed 9 Aug 2023.